NCT03911453 2024-10-03Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsUniversity of ArizonaPhase EARLY_PHASE1 Completed20 enrolled